UNSPSC 51263013: Terazosin monohydrochloride dihydrate

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C19H25N5O4.ClH.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D32S14F082, chemically known as methanone, (4-(4-amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinyl)(tetrahydro-2-furanyl)-, hydrochloride, hydrate (1:1:2), but more generally known as terazosin monohydrochloride dihydrate, which bears US NIH Compound Identifier 63016.

European Medicines Agency schedules terazosin monohydrochloride dihydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10907MIG. Most nations, for tariff purposes, schedule terazosin monohydrochloride dihydrate under HS 29349990. SMILES: COC1CC2C(CC1OC)NC(NC2N)N3CCN(CC3)C(=O)C4CCCO4.O.O.CL.

UNSPSC 51263013 Terazosin monohydrochloride dihydrate is a Commodity code that nominally describes a specific pharmaceutical active ingredient, but recent state and local opportunities under this code show little alignment with its formal scope. The two recent solicitations tagged to this code — one from Seminole County, Florida procuring naloxone and drug deactivation systems, and a Request for Information from the Texas Health and Human Services Commission on direct-to-manufacturer prescription programs — do not represent purchases of terazosin monohydrochloride dihydrate or related pharmaceutical inputs. The code sees activity from health and human services agencies at the county and state level, but the mismatch between the code's nominal scope and what is actually being bought suggests either tagging error in the source system or a structural divergence between the UNSPSC taxonomy and current procurement practice for pharmaceutical commodities at the state and local level.

Geographic activity appears concentrated in Texas and Florida based on the two posted opportunities. Seminole County's IFB (IFB60459723LAS), posted June 30, 2026 with a response deadline of July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building. The Texas HHS Commission's RFI (HHS0017013), posted April 3, 2026, gathered vendor capability information on direct-to-manufacturer prescription programs for state employee and retiree health plans. Neither opportunity directly relates to the terazosin commodity this code nominally describes. Firms pursuing pharmaceutical supply contracts at the state and local level should monitor this code with caution and verify that specific solicitations align with their product or service line before committing bid resources.